In a Thursday SEC filing, Ligand said Viking materially breached its duty to use commercially reasonable efforts to develop and commercialise the programme.
Ligand said the licence agreement requires Viking, after termination, to grant it a non-exclusive global royalty-bearing licence for products developed under the TR-Beta programme.
Viking is disputing Ligand's right to terminate the programme, while Ligand said it believes the move is valid under the agreement and will enforce that right.
Will a legal battle between biotechs delay a breakthrough treatment for millions with liver disease?
Is this a valid contract dispute or an aggressive 'royalty grab' enabled by recent court rulings?